Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun;54(6):567-71.
doi: 10.1016/j.jinf.2006.11.007. Epub 2006 Dec 26.

Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients

Debra D Poutsiaka  1 , Serena Skiffington, Kenneth B Miller, Susan Hadley, David R Snydman
Affiliations

Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients

Debra D Poutsiaka et al. J Infect. 2007 Jun.

Abstract

Objective: Vancomycin resistant enterococcal (VRE) blood stream infection (BSI) in neutropenic patients is associated with poor outcome. We report our experience in treating VRE BSI in febrile, neutropenic patients with daptomycin, a recently licensed lipopeptide with bactericidal activity against VRE.

Patients and methods: Patients with fever, neutropenia and VRE BSI were treated with more than one dose of daptomycin (either 6 mg/kg/day or 4 mg/kg/day) in an open label, emergency-use trial. Patients were then assessed for clinical and microbiological cures and survival. MIC's of isolates to daptomycin were determined.

Results: Nine febrile, neutropenic patients with VRE BSI received daptomycin. Four of 9 courses (44%) had clinical and/or microbiologic cure. Two of the 5 who failed cure died within 3 days of initiation of daptomycin. Five subjects survived to 30 days after the onset of BSI.

Conclusions: Use of daptomycin in neutropenic patients with VRE BSI deserves further study as a treatment for VRE BSI in neutropenic patients.

PubMed Disclaimer

References

    1. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. Journal of Infectious Diseases. 2005;191(4):588–95. - PubMed
    1. Koc Y, Snydman DR, Schenkein DS, Miller KB. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Bone Marrow Transplantation. 1998;22(2):207–9. - PubMed
    1. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Annals of Internal Medicine. 2001;135(7):484–92. - PubMed
    1. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrobial Agents & Chemotherapy. 2001;45(2):454–9. - PMC - PubMed
    1. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM. Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrobial Agents & Chemotherapy. 2000;44(12):3447–50. - PMC - PubMed

Publication types